Emerging Biopharma Shifts Focus to Multinational Clinical Trials

This Fierce Biotech content from Questex focuses on the multinational clinical trial (MRCT) strategies of emerging biopharma companies, rather than specific drugs or indications. According to IQVIA, these companies account for approximately 65% of new drug candidates, and in 2018, they conducted 65% of all clinical trials. For companies with limited internal resources and capital, managing scientific differentiation, country selection, patient recruitment, and data quality as a single capital allocation problem is crucial.

MRCTs Reduce Redundancy in Later-Stage Development

MRCTs involve recruiting patients from multiple regions using a common protocol to simultaneously assess the impact of both intrinsic and extrinsic factors on treatment efficacy. ICH E17, finalized by the U.S. FDA in July 2018, outlines common principles for confirmatory trials, regional sample distribution, and the evaluation of result consistency, and is also applied to the EMA and Japan's PMDA review systems. By coordinating regional dosages, standard treatments, and outcome measures from Phase 2, the need for separate bridging studies and the risk of regulatory delays after Phase 3 can be reduced.

Market Expansion Supports CRO Demand

Grand View Research estimates the global clinical trial market at USD 89.0 billion in 2025 and USD 94.0 billion in 2026, projecting a compound annual growth rate of 7.7% to USD 158.4 billion by 2033. In this market, IQVIA Holdings (IQV), ICON plc (ICLR), Parexel International, Labcorp Holdings (LH), and Thermo Fisher Scientific's (TMO) PPD compete based on their global site networks and regulatory execution capabilities. For emerging biopharma, the actual track record of enrolling patients in target indications, country-specific patient access, data integration capabilities, and budget accountability are more important selection criteria than the CRO brand.

APAC: Recruitment Capabilities are Key, Not Just Cost

Including China, South Korea, Japan, and Australia, the APAC region can leverage large patient populations and specialized clinical institutions to supplement North America-centric recruitment. However, simply adding low-cost countries is not enough; local standard treatments, diagnostic pathways, sample logistics, and data privacy regulations must be incorporated into the protocol and statistical analysis plan. If the number of patients in each region is too small, it will be difficult to explain the consistency of the treatment effect, so initial simulations and regulatory agency consultations should precede cost reduction efforts.

From an Investment Perspective, Data Reusability is Valuable

This material does not include specific brand names, generic names, target molecules, clinical trial registration numbers, product approvals, or AdComm results, nor does it evaluate competition between specific therapies. The key is to design a global data package that can extend from Phase 1 to the approval and marketed stages, reducing the need for additional trials and cash burn. While no specific licensing or equity investment terms are presented, reusable data across regulatory regions is an asset that influences development timelines, success rates, and capital requirements in subsequent investments and licensing due diligence.